Varun Mehra

Haematologist @KingsCollegeNHS @myeloidkings #StemcellTransplantation #GVHD #MedicalMycology #loveToNetwork #BloodCancerResearch

[John Strouboulis @JohnStrouboulis]

Looking for a new Professor of Haematology and Head of the Department of Haematology at King's College London, based in the Denmark Hill campus. Closing date: May 4. For more info: https://t.co/GSNEKnuZJN
@KHPHaematology
@KCLcancer_pharm
@KCLredcell
@kingsmedicine

[Uriel Suárez @UsuarezMD]

American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia | Blood Advances | American Society of Hematology https://t.co/uWaQ5bdlMu

[Varun Mehra @docbmt]

#Mycology2026 start today! Everything related to Fungal diseases with some excellent line up of speakers, new updates and innovations in the field!
Come join for some exciting interactions and networking with experts in the field.
@FungalUpdate

https://t.co/g7wsQ0f6DG

[GvHD Hub @gvhd_hub]

CONGRESS | #EBMT26 | PRESENTATION

Florent Malard reports final results from the phase III, multicenter, open-label ARES trial, evaluating MaaT013 as a third-line treatment option in patients with treatment-refractory GI-#aGvHD after systemic steroids and ruxolitinib (N = 66). ARES met its primary endpoint, with a Day 28 GI-ORR of 62%, exceeding the pre-established threshold of 22% (p < 0.0001). Most patients had Day 28 GI-CR (38%) or GI-VGPR (20%), with 5% experiencing GI-PR. The all-organ ORR at Day 28 was 64%, and GI-ORR was maintained in 47% at Day 56 and 44% at Month 3. With a median follow-up of 344.5 days, the median OS was not reached; OS was 54% at Month 12, and was higher among Day 28 responders vs non-responders (68% vs 28%).

Follow our live feed for more updates: https://t.co/zjpTpxi8OS

Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.

#GvHDsm #MedNews #MedEd @TheEBMT @Florent_Malard @crsa_paris

[Varun Mehra @docbmt]

Super important piece for GVHD community.

[Uriel Suárez @UsuarezMD]

Chronic graft-versus-host disease: Current situation and unmet needs — A European position statement | Bone Marrow Transplantation ⁦@Mohty_EBMT⁩ https://t.co/LVtIlj2kzT

[Varun Mehra @docbmt]

Time to step up and diligently apply regulatory framework for emerging novel therapeutic class (SoHO, Substances of Human Origin) in #HSCT and #GVHD.

@Mohty_EBMT @TheEBMT
https://t.co/ejF4clEkN3

[GvHD Hub @gvhd_hub]

CONGRESS | #ASH25 | POSTER
Everett Meyer presents data from a subgroup analysis of the phase III Precision-T trial of Orca-T versus tacrolimus + methotrexate (Tac/MTX) in patients with acute leukemia (N = 182).

At 1 year, Orca-T demonstrated improved rates of chronic GvHD-free survival (78% vs 38%; p < 0.0001), OS (94% vs 83%; p = 0.045), GRFS (63% vs 31%; p < 0.0001), and NRM (13% vs 3.4%; p = 0.037) compared to Tac/MTX. Orca-T vs Tac/MTX showed improved clinical outcomes across patient subgroups with varied demographic and clinical features, including age, sex, donor type, and conditioning regimen.

Follow our live feed for more updates: https://t.co/VFzAJAtDt8
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#GvHD #GvHDsm #MedicalCongress @StanfordMed

[Varun Mehra @docbmt]

Inviting all HCPs involved in care for stem cell transplant patients to our 1st KHP Preceptorship Event (3/4th Sept 2025) for Transplant complications with #GVHD

This is a limited space event, so book early..

Registration/program details below..

https://t.co/JZBiN6aXpz

[LARVOL @Larvol]

AML at @EHA_Hematology 2025: Inqovi, Ziftomenib, Bleximenib, and More.
Key updates on ORR, CR/CRi rates, and tolerability.

Follow us for the latest #EHA2025 updates: https://t.co/GlFVhoEY2I

#LARVOL #AML #Hematology #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @AlkaliDr | @LeukDocJZ | @calliecoombsmd | @hemedoc | @AaronGoodman33 | @TalhaBadarMD | @SuyogCancer

[NEJM @NEJM]

Original Article: Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin (ALLG BM12 CAST phase 3 trial) https://t.co/Zg3IPtTGId

#EHA2025 | @EHA_Hematology

[LARVOL @Larvol]

Menin inhibitor studies at @EHA_Hematology 2025 in acute leukemia, focusing on NPM1-mutated and KMT2A-rearranged subsets.

Follow us for the latest #EHA2025 updates: https://t.co/GlFVhoEqda

#LARVOL #Hematology #Leukemia #CancerResearch #Oncology #CancerData #OncologyInsights | @Dr_AmerZeidan | @TalhaBadarMD | @smbenlazar | @hemedoc | @LeukDocJZ | @Abdallah81MD | @SuyogCancer

[Blood Advances @BloodAdvances]

a comprehensive report of the survival outcomes among 240 patients who underwent a transplant at the MD Anderson Cancer Center for acute myeloid leukemia AML or myelodysplastic syndrome with TP53 mutations over a 10-year period. https://t.co/zLbgeLyntR #transplantation

[Varun Mehra @docbmt]

5. Key problem is inequity of access with some regions in UK undertaking markedly less activity. Need more awareness.

[Varun Mehra @docbmt]

Hot off the press!

Our UK wide 20years experience of Autologous #HSCT in #MultipleSclerosis reaffirming its significant benefits even with advanced disability
@BSBMT @BritSocHaem @BrJHaem @TheEBMT @KingsCollegeNHS @mssocietyuk @MSTrust
Key findings👇🏻
https://t.co/ax20f9L0iw

[Varun Mehra @docbmt]

3. First report confirming more immunosuppression i.e. higher ATG doses do not confer additional benefit. Harmonised dosing essential!
4. Transplant related Mortality risk &lt;1.5%, mainly seen with advanced disability and needs better optimisation/ careful selection essential

[Varun Mehra @docbmt]

Finally out.. 3rd edition of #COVID guidance by ECIL-10👇🏻🙏

Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy
@TheEBMT @BritSocHaem @BSBMT @CDCgov @EHA_Hematology

https://t.co/sAxORgGqNY

[Vincent Alcazer @AlcazerVincent]

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)
https://t.co/UPfeqSPnU7

[Varun Mehra @docbmt]

Real world study now out from our London MS HSCT group showing superior Effectiveness of Autologous #HSCT versus Alemtuzumab and Ocrelizumab in Relapsing #MultipleSclerosis @BSBMT @TheEBMT @KingsCollegeNHS @imperialcollege
@TheNewANA1

https://t.co/sylQdXJXDm

[Felipe Peña-Muñoz @HematoRules]

Take home messages on cGvHD #EBMT25 @Mohty_EBMT

Best Belumosudil response takes time!
&gt;6mo to achieve it in some cases

Most important…
Great Impact on QoL!
Very well tolerated treatment
Good safety profile
Great responses in heavily pretreated patients

@TheEBMT